Breakthrough in Diffuse Large B-Cell Lymphoma Treatment
In a significant advancement in the treatment of diffuse large B-cell lymphoma (DLBCL), Genmab’s investigational therapy, epcoritamab, in combination with rituximab and a salvage regimen of ifosfamide, carboplatin, and etoposide (R-ICE), has demonstrated remarkable efficacy in patients with relapsed or refractory DLBCL eligible for autologous stem cell transplantation (ASCT). The results were shared during a high-profile oral session at a recent European Hematology Association (EHA) Congress.
Study Results Highlight High Response Rates
Impressive Overall and Complete Response Rates
The EPCORE NHL-2 trial reported a striking overall response rate (ORR) of 87% and a complete response (CR) rate of 65%. These promising results are particularly noteworthy as they indicate that many patients previously considered difficult to treat responded positively to this innovative combination therapy. With 65% of participants advancing to ASCT, these results further reinforce the potential of epcoritamab as a transformative treatment option.
Safety Profile of Epcoritamab Combination Therapy
Adverse Effects and Management
The combination therapy exhibited a manageable safety profile, with low-grade cytokine release syndrome (CRS) reported in 52% of patients. Notably, there were no discontinuations linked to treatment-emergent adverse events (TEAEs). The most frequently observed TEAEs included neutropenia, anemia, and thrombocytopenia, with resolution reported for all occurrences of CRS. This favorable safety profile suggests the potential for broad applicability in clinical practice.
Significance for High-Risk Patients
Addressing an Unmet Need
Raul Cordoba, MD, PhD, emphasized the importance of these results for high-risk patients who have rapidly progressed after initial therapies. The combination of epcoritamab with R-ICE presents an exciting new avenue for treatment, not just to achieve favorable responses but to potentially pave the way for curative interventions through ASCT.
Further Insights from the Trial
Variation in Response Rates by Treatment History
Interestingly, response rates varied among different patient subgroups. Patients who had progressed within 12 months of initial treatment showed an ORR of 85%, while those with more than a year since first-line therapy experienced an ORR of 91%. This highlights the dual potential of epcoritamab: effective for both early relapses and late progressions in DLBCL.
About Genmab and Its Commitment
Genmab continues to lead the charge in advancing therapies for hematologic malignancies. As the company collaborates with AbbVie, it aims to explore epcoritamab not just in DLBCL but also across a variety of lymphomas and treatment regimens. The ongoing trials signal a commitment to addressing significant gaps in treatment options for patients facing this challenging disease.
About Epcoritamab
Epcoritamab, leveraging Genmab's DuoBody technology, is engineered to direct cytotoxic T cells against B-cell targets, effectively bridging a critical gap in current lymphoma therapies. This bispecific antibody is designed to bind selectively to CD3 on T cells and CD20 on B cells, enhancing the immune responses against malignancies.
Frequently Asked Questions
What is the significance of the EPCORE NHL-2 trial?
The trial demonstrates the high effectiveness of epcoritamab combined with R-ICE in treating relapsed/refractory DLBCL, showing promising response rates.
What were the overall response rates reported?
The EPCORE NHL-2 trial reported an overall response rate of 87% and a complete response rate of 65% among treated patients.
What are the common side effects associated with this therapy?
The most common side effects include neutropenia, anemia, and thrombocytopenia, with low-grade cytokine release syndrome observed in some patients.
How does this treatment option impact high-risk patients?
This combination therapy provides a potential new path for high-risk patients who previously had limited options following rapid disease progression.
What is the future direction for Genmab and epcoritamab?
Genmab and AbbVie are focusing on expanding the indications for epcoritamab, conducting several ongoing trials to explore its use in various lymphoma settings and treatment lines.
